Celgene reports Phase II data for Otezla in UC

Celgene Corp. (NASDAQ:CELG) reported data from a Phase II trial in 170 patients with active ulcerative colitis (UC) showing that twice-daily 30 and 40 mg doses of

Read the full 272 word article

User Sign In